TRYPTYR FDA Approval — TRPM8 Agonist Eye Drops. Perimenopausal Women's Dry Eye Blind Spot New Target
SCIENCE

TRYPTYR FDA Approval — TRPM8 Agonist Eye Drops. Perimenopausal Women's Dry Eye Blind Spot New Target

By Maya · · Alcon / FDA Approval
KO | EN

Perimenopausal women’s dry eye is common but lacks specific clinical data. After artificial tears·Restasis(2003)·Xiidra(2016)·Cequa(2018), no new target. Alcon TRYPTYR 2026.4 FDA approval = first TRPM8 receptor direct stimulation new target. Simultaneously Aldeyra reproxalap PDUFA 2026.3.16 = simultaneous dry eye visualization.

Key Announcement

TRYPTYR (acoltremon 0.003% eye drops): First-in-class TRPM8 receptor agonist, FDA approved 2026.4, dry eye indication, 1~2x/day instillation

Aldeyra reproxalap: RASP (reactive aldehyde species) modulator, PDUFA 2026.3.16, dry eye + allergic conjunctivitis

Dry Eye and Women — Blind Spot

Prevalence:

  • Korean women 30~50% (40+)
  • Perimenopausal women = 2x men
  • 50~70s women most common

Causes:

  • Estrogen·androgen ↓ → meibomian·lacrimal gland function ↓
  • Autoimmune (Sjogren·lupus)
  • Contact lens·digital screen

Existing treatment limits:

  • Effect onset 1~3 months
  • Side effects (instillation irritation·burning)
  • Some non-responders

TRPM8 Receptor — New Target

TRPM8 (Transient Receptor Potential Melastatin 8):

  • Cool·mint sensation receptor
  • Corneal nerve distribution
  • Stimulation → tear secretion signal

Acoltremon mechanism:

  • TRPM8 direct agonist
  • Corneal cool sensation activation
  • Reflex tear secretion
  • Cool sensation + tears upon instillation

Clinical difference:

  • Artificial tears: external supplement
  • Immunosuppression: ↓ inflammation
  • TRPM8: self-tear stimulation

TRYPTYR Clinical Data

Phase 3: Immediate tear volume ↑ post-instillation, symptom improvement within 1 week, side effects: cool sensation·transient irritation, 12-week sustained effect

Comparison:

  • Restasis: 1~3 months effect
  • TRYPTYR: immediate~1 week
  • Good safety profile

Perimenopausal Women - Hormone & Dry Eye

Connection mechanism:

  • Estrogen ↓ → meibomian gland (eyelid oil gland) function ↓
  • Androgen ↓ → lacrimal gland secretion ↓
  • Autoimmune risk ↑ (Sjogren etc)
  • Autonomic instability → secretion ↓

Perimenopausal characteristics:

  • ↑ symptom severity
  • Nighttime worsening
  • Contact lens impossible
  • Digital screen exacerbation

L71 Blind Spot Dimension - First Axis

L70 40 pillars covered drugs·environment·diagnosis·daily. But ophthalmology blind spot was missing. L71 TRYPTYR = first of 5 blind spot axes.

40 pillar connections:

  • L66 Auvelity Alzheimer (CNS drug) → L71 TRYPTYR ocular neural channel
  • L65 new retinol (skin) → L71 TRYPTYR ocular signaling (sensory receptor)
  • L67 OS-01 senolytic → L71 TRYPTYR aging organ (eye)

Aldeyra reproxalap - Second Ophthalmology Target

RASP modulator: Ocular surface aldehyde species blockade, inflammation + allergy simultaneous target, PDUFA 2026.3.16

Meaning: Dry eye single-target era → multi-target era. Patient-personalized (TRPM8 vs RASP)

Korean Clinical Implications

Current Korea: Artificial tears (1st line), Restasis (post-pricing), Xiidra·Cequa (partial Korea), IPL for meibomian gland dysfunction

TRYPTYR adoption expected: Korean MFDS approval 2026~2027 expected, price $200~$300/month US, Korean insurance TBD

Self-Assessment

OSDI (Ocular Surface Disease Index):

  • 12 questions
  • 13+ = possible dry eye
  • 33+ = severe

Signs: Eye burning·foreign body sensation, blurry vision (tear instability), contact lens discomfort, digital screen worsening

Daily Management

Basic: Digital screen 20-20-20, indoor humidity 40~60%, humidifier, artificial tears (preservative-free preferred)

Diet: Omega-3 (FAA 1,000mg+), vitamin A·D, hydration (1.5~2L/day)

Procedures: Meibomian gland IPL, punctal plug

Treatment ladder: Artificial tears → immunosuppression (Restasis/Xiidra) → TRYPTYR (immediate effect)

FAQ

Q. TRYPTYR vs artificial tears? A. Artificial tears = external supplement temporary. TRYPTYR = self-tear stimulation sustained. Doctor consult for stage.

Q. Especially good for perimenopausal women? A. Yes. Immediate effect appeals to hormone decline·meibomian gland dysfunction common in perimenopause. Ophthalmologist consult.

Q. Cool sensation a side effect? A. Not side effect, mechanism (TRPM8 = cool receptor). Some discomfort. Adaptable.

Q. When available in Korea? A. Post-FDA approval Korean MFDS review 2026~2027. Some ophthalmology prescription possible.

Conclusion

TRYPTYR FDA approval + Aldeyra reproxalap PDUFA = simultaneous ophthalmology blind spot visualization. Perimenopausal women’s dry eye = hormone·immunosuppression·neural channel multi-target era. L71 = 40 pillars + blind spot dimension (ophthalmology 1st axis). Korea adoption 2026~2027 expected. Beyond artificial tears·immunosuppression limits = self-tear stimulation new dimension.

Source: Alcon / FDA Approval